OncoMatch/Clinical Trials/NCT06454578

Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection

Is NCT06454578 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Adebrelimab + Apatinib for carcinoma, hepatocellular.

Phase 2RecruitingQilu Hospital of Shandong UniversityNCT06454578Data as of May 2026

Treatment: Adebrelimab + Apatinib — This is a single-center, single-arm, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib as adjuvant therapy in hepatocellular carcinoma (HCC) participants who are at high risk of recurrence after curative resection.

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Disease stage

Grade: Edmondson IIIEdmondson IV (Edmondson)

poor tumor differentiation (Edmondson III-IV grade)

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Must have received: curative resection surgery

Within 4-12 weeks prior to enrollment, radical resection surgery was performed.

Cannot have received: systematic anti-tumor treatment

Have not received systematic anti-tumor treatment for hepatocellular carcinoma in the past.

Cannot have received: local treatment (therapeutic TACE, transarterial embolization (TAE), hepatic artery infusion chemotherapy (HAIC), transarterial radiation embolization (TARE))

Previously received local treatment, including therapeutic TACE, transarterial embolization (TAE), hepatic artery infusion chemotherapy (HAIC), transarterial radiation embolization (TARE), etc.

Lab requirements

Blood counts

Neutrophil absolute count ≥ 1.5 × 10^9/L; Platelets ≥ 75 × 10^9/L; Hemoglobin ≥ 90 g/L

Kidney function

Blood creatinine ≤ 1.5 x ULN or Cr clearance rate >50ml/min

Liver function

Child Pugh liver function rating: A or B (≤ 7 points); Serum albumin ≥ 28g/L; Total serum bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 3 × ULN

Cardiac function

NYHA level II or above cardiac insufficiency or cardiac ultrasound: LVEF <50%; unstable angina; MI within 1 year; significant arrhythmias; QTc >480ms

The main organ functions meet the following requirements... (see full criteria for details)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify